Molnupiravir - Covid-19

You are here : Home > Formulary Search > Molnupiravir - Covid-19

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red

Formulations :

Capsules

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

NICE

SPC

Restrictions / Comments :

Important

Primary care and outpatient prescribing of antivirals for COVID 19 treatment is through the CMDU service.

Hospital inpatients - as per local hospital guidelines

Documentation

NICE Technology Appraisal

Molnupiravir for treating COVID-19 NICE TA1056

Evidence Review

NICE TA878 CMDU APC briefing paper Jun-23.doc

Information

CMDU Community Pharmacies June 2025.pdf

PAD Profile

ChemicalSubstance :

Molnupiravir

Indication :

Covid-19

Group Name :

Keywords :

Covid 19, Coronavirus, antivirals

Brand Names Include :

Lagevrio

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Molnupiravir is used to treat.

No records returned.

Other Drugs

Below are listed other drugs that are used to treat Covid-19.

Committee Recommendations (1)

04 Jun 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed that molnupiravir (Lagevrio) should be made available in line with NICE TA1056 for the treatment of COVID-19 for people who are at highest risk of becoming seriously ill as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 only if both nirmatrelvir plus ritonavir and sotrovimab are contraindicated or unsuitable.

It is considered as a RED drug and should only be prescribed by individuals who have been assessed by the Covid Medicines Delivery Unit (or if a patient who falls into one of the highest-risk cohorts is in hospital and gets COVID-19 whilst an inpatient). Not for prescribing through A&E / hospital clinics.